- Policy
- “Impartiality of reimbursement review system undermined"
- by Lee, Jeong-Hwan Oct 18, 2021 05:54am
- The principal investigator of the clinical trial of lung cancer drug B participated in lung cancer A drug’s reimbursement assessment meeting. Isn’t this a conflict of interest and cause for the member’s exclusion from the committee?” (People Power Party Jung-sook Suh) “There are operational regulations set for the Cancer Disease Delib
- Policy
- Introduction of CDF for Zolgensma was proposed
- by Lee, Hye-Kyung Oct 18, 2021 05:54am
- When the National Assembly proposed the introduction of the Cancer Drugs Fund (CDF) for Zolgensma, the NHIS accepted the beginning of the discussion. Rep. Kim Sung-joo of the Democratic Party of Korea said in a parliamentary audit of the National Assembly's Health and Welfare Committee on the 15th, "There was a story of a new drug worth 2.
- Policy
- The HIRA also decided to disclose the results of Kymriah
- by Lee, Hye-Kyung Oct 15, 2021 05:58am
- The HIRA has decided to disclose the results of the drug benefit assessment. Although the entire evaluation process required by citizens, patient organizations, and the pharmaceutical industry is not disclosed in detail, it has decided to clearly disclose the establishment of benefit standards and appropriateness of benefits. The HIRA rele
- Policy
- Requests for confirmation of medical expenses, disclosed
- by Lee, Hye-Kyung Oct 15, 2021 05:57am
- After Avastin receiving the indication of macular degeneration, a patient who paid at his own expense requested confirmation of medical expenses, but the non-reimubrsed cases was justified. The HIRA released a case of requesting confirmation of non-reimbursed medical expenses in the third quarter. Patients can check the details of medical
- Policy
- A new drug preferential law will be promoted
- by Lee, Jeong-Hwan Oct 15, 2021 05:57am
- The MOHW announced that it will start enacting subordinate laws to substantially implement and secure the effectiveness of the "clause for preferential treatment of new domestic drugs" developed by innovative pharmaceutical companies under the Special Act on the Pharmaceutical Industry. The "upper limit price preferential treatment of drug
- Policy
- No need to extend the benefit period of Keytruda
- by Lee, Jeong-Hwan Oct 14, 2021 05:38am
- The MOHW said there is little need to extend the benefit period of Keytruda, an immuno-cancer drug, for patients who are effective in secondary treatment of non-small cell lung cancer by more than two years. This is because the clinical period of Keytruda was designed to be two years, and related societies such as the Korean Association fo
- Policy
- Poor ‘Benefit Adequacy Assessment' in controversy
- by Lee, Jeong-Hwan Oct 14, 2021 05:38am
- A bill to specify the basic definition of the Insurance Benefit Adequacy Assessment and stipulate the submission period for its data for assessment is being promoted. On the 13th, the National Assembly member Jong-Sik Heo announced that he had presented a bill for the partial amendment of the National Health Insurance Act that contained t
- Policy
- # of COVID-19 confirmed medical staff doubled in 3 months
- by Lee, Jeong-Hwan Oct 14, 2021 05:37am
- Among domestic medical personnel, the cumulative number of confirmed cases of COVID-19 has more than doubled compared to three months ago. Out of a total of 321,352 COVID-19 confirmed patients as of 0 o'clock on the 5th, 5,444 were medical personnel or medical institution workers. On the 12th, Choi Yeon-sook of the People Party made this anno
- Policy
- Suspicions of preferential tx for SK Bioscience & Celltrion
- by Lee, Tak-Sun Oct 14, 2021 05:37am
- Suspicions have been raised during a parliamentary audit, led by opposition lawmakers, that the MFDS may have provided preferential treatment to the company for domestic COVID-19 drugs. Kim Kang-rip, head of the MFDS, dismissed the suspicion, saying he approved it based on evidence. Fentanyl Patch, a drug pain reliever, is being used by t
- Policy
- MFDS will quickly & thoroughly verify Merck's COVID-19 tx
- by Lee, Tak-Sun Oct 13, 2021 05:46am
- It was pointed out that Merck's oral treatment, which is considered a COVID-19 game changer, should be quickly introduced in Korea. Kang Ki-yoon, a member of the People Power Party, said in a parliamentary audit of the MFDS held at the National Assembly on the 8th, "Oral treatments are needed during the With Corona," stressing, "Not only
